- Home
- TIL vs ACHV Comparison
TIL vs ACHV Comparison
Compare TIL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- ACHV
- Stock Information
- Founded
- TIL 2018
- ACHV N/A
- Country
- TIL United States
- ACHV United States
- Employees
- TIL N/A
- ACHV N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TIL Health Care
- ACHV Health Care
- Exchange
- TIL Nasdaq
- ACHV Nasdaq
- Market Cap
- TIL 177.1M
- ACHV 167.6M
- IPO Year
- TIL 2021
- ACHV N/A
- Fundamental
- Price
- TIL $12.74
- ACHV $4.30
- Analyst Decision
- TIL Strong Buy
- ACHV Strong Buy
- Analyst Count
- TIL 5
- ACHV 1
- Target Price
- TIL $100.67
- ACHV $12.00
- AVG Volume (30 Days)
- TIL 62.5K
- ACHV 940.7K
- Earning Date
- TIL 11-13-2025
- ACHV 11-06-2025
- Dividend Yield
- TIL N/A
- ACHV N/A
- EPS Growth
- TIL N/A
- ACHV N/A
- EPS
- TIL N/A
- ACHV N/A
- Revenue
- TIL N/A
- ACHV N/A
- Revenue This Year
- TIL N/A
- ACHV N/A
- Revenue Next Year
- TIL N/A
- ACHV N/A
- P/E Ratio
- TIL N/A
- ACHV N/A
- Revenue Growth
- TIL N/A
- ACHV N/A
- 52 Week Low
- TIL $10.80
- ACHV $1.84
- 52 Week High
- TIL $42.79
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- TIL 31.33
- ACHV 47.76
- Support Level
- TIL $13.53
- ACHV $4.26
- Resistance Level
- TIL $16.00
- ACHV $4.90
- Average True Range (ATR)
- TIL 1.32
- ACHV 0.33
- MACD
- TIL -0.22
- ACHV -0.13
- Stochastic Oscillator
- TIL 7.95
- ACHV 4.31
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.